RNA-binding proteins (RBPs) play a critical role in the regulation of various RNA processes,
including splicing, cleavage and polyadenylation, transport, translation and degradation of …

Myelofibrosis (MF) is a myeloproliferative disorder that exhibits considerable biological and
clinical heterogeneity. At the two ends of the disease spectrum are the myelodepletive or …

Although other mutations may predate the acquisition of the JAK2 V617F mutation, the latter
is sufficient to drive the disease phenotype observed in BCR-ABL-negative …

The evolutionarily-conserved La-related protein (LARP) family currently comprises Genuine
La, LARP1, LARP1b, LARP4, LARP4b, LARP6 and LARP7. Emerging evidence suggests …

A limited number of drugs are available to treat patients with polycythemia vera (PV) and
essential thrombocythemia (ET). We attempted to identify alternative agents that may target …

Despite recent advances, the myeloproliferative neoplasms (MPNs) are attended by
considerable morbidity and mortality. Janus kinase (Jak) inhibitors such as ruxolitinib …

Polycythemia vera (PV) is mainly characterized by elevated blood cell counts, thrombotic as
well as hemorrhagic predisposition, a variety of symptoms, and cumulative risks of fibrotic …

Reactive oxygen species (ROS) have been implicated in a wide variety of disorders ranging
between traumatic, infectious, inflammatory, and malignant diseases. ROS are involved in …

The myeloproliferative neoplasms (MPN), polycythaemia vera (PV), essential
thrombocythemia (ET) and primary myelofibrosis (PMF) are linked by a propensity to …

Patients with myelofibrosis (MF) who discontinue ruxolitinib due to progression/resistance
have poor prognoses. JAK inhibitors control symptoms and reduce spleen volumes with …